EGFR and neoplasm: Existing case studies [99, 100] indicate that EGFR‐TKI‐treated EGFR‐mutant NSCLC patients may develop PTB or PTB reactivation, possibly related to non‐TB lesion area Mtb reactivation caused by LC or increased opportunistic infection risk due to tumor treatment‐induced immunosuppression.